<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Clemmensen, Peter</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-Term Results of the DEDICATION Trial Favor the Use of DES over BMS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-18</style></pages><abstract><style  face="normal" font="default" size="100%">According to long-term follow-up results from the Drug Elution and Distal Protection During Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction [DEDICATION; NCT00192868] trial, drug-eluting stents (DES) reduced the rate of major adverse cardiac events and were not associated with an increased rate of myocardial infarction or stent thrombosis compared with bare-metal stents. However, an increased incidence of cardiac death was observed in the DES group.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>